novo nordisk is cutting prices on its popular glp-1 drugs. cuts of Ozempic, Wegovy, and Rybelsus by up to 50% Novo Nordisk is slashing GLP-1
Description
New therapies are exploring alternative mechanisms for targeting obesity and promoting weight loss, as well as new methods of administration that could be more convenient and discreet for patients
Danish pharmaceutical company Novo Nordisk started making Ozempic to help people with diabetes
July 23, 2024
After bariatric surgery we learned that metabolic improvement occurred long before significant amounts of fat mass have been lost
It belongs to the same class of medications (GLP-1 RAs) and is used for the treatment of Type 2 Diabetes mellitus as well as weight loss
PMCID: PMC12808432
